Skip to main content

Arbe Robotics Ltd. (ARBE) Stock Forecast

Data as of May 2, 2026

Technology · Current price $0.84 (-1.74%)

Consensus Target
$2.00
Upside
+138.1%
Analysts
2
Rating
Buy(2.00)

Price Target Range

Low $2.00High $2.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Aug 8, 2025Suji DesilvaRoth Capital$2.00+138.1%

ARBE vs Sector & Market

MetricARBETechnology AvgLarge Cap Avg
Analyst Rating2.002.342.41
Analyst Count21318
Target Upside+138.1%+4072.5%+14.9%
P/E Ratio-1.9227.9431.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$3M$5M$6M2
2027-12-31$15M$22M$29M3
2028-12-31$52M$74M$96M2
2029-12-31$84M$120M$156M1
2030-12-31$110M$159M$205M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.40$-0.29$-0.181
2027-12-31$-0.33$-0.23$-0.142
2028-12-31$-0.06$-0.04$-0.032
2029-12-31$0.06$0.10$0.141
2030-12-31$0.13$0.21$0.291

Frequently Asked Questions

What is the analyst consensus for ARBE?

The consensus among 2 analysts covering Arbe Robotics Ltd. (ARBE) is Buy with an average price target of $2.00.

What is the highest price target for ARBE?

The highest price target for ARBE is $2.00, set by Suji Desilva at Roth Capital on 2025-08-08.

What is the lowest price target for ARBE?

The lowest price target for ARBE is $2.00, set by Suji Desilva at Roth Capital on 2025-08-08.

How many analysts cover ARBE?

2 analysts have issued ratings for Arbe Robotics Ltd. in the past 12 months.

Is ARBE a buy or sell right now?

Based on 2 analyst ratings, ARBE has a consensus rating of Buy (2.00/5) with a +138.1% upside to the consensus target of $2.00.

What are the earnings estimates for ARBE?

Analysts estimate ARBE will report EPS of $-0.29 for the period ending 2026-12-31, with revenue estimated at $5M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.